PMID- 27775949
OWN - NLM
STAT- MEDLINE
DCOM- 20170109
LR  - 20191210
IS  - 1536-0229 (Electronic)
IS  - 0363-9762 (Linking)
VI  - 42
IP  - 1
DP  - 2017 Jan
TI  - Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on 
      Preoperative 18F-FDG PET/CT in Patients With Very Early and Early Hepatocellular 
      Carcinoma.
PG  - 34-39
AB  - PURPOSE: The aim of this article was to evaluate the prognostic value of 
      metabolic tumor volume (MTV) and total lesion glycolysis (TLG) on preoperative 
      F-FDG PET/CT for predicting intrahepatic recurrence-free survival (IHRFS), 
      extrahepatic metastasis-free survival (EHMFS), and overall survival (OS) in 
      patients with very early/early hepatocellular carcinoma (HCC). PATIENTS AND 
      METHODS: We retrospectively enrolled 132 patients with very early/early HCC who 
      underwent F-FDG PET/CT followed by surgery. The maximum tumor SUV-to-mean normal 
      liver SUV ratio, MTV, and TLG were measured for each patient. Prognostic 
      significances of PET/CT parameters and clinicopathologic factors for IHRFS, 
      EHMFS, and OS were evaluated. Cumulative IHRFS, EHMFS, and OS were calculated 
      using the Kaplan-Meier method. RESULTS: Thirty-three (25%) and 21 (15.9%) of 132 
      patients experienced intrahepatic and extrahepatic recurrence, respectively, 
      during a median follow-up period of 38.1 months. In multivariate analysis, none 
      of the factors were significant for IHRFS. Metabolic tumor volume and TLG were 
      only significant factors for EHMFS and OS (P < 0.05). The 5-year EHMFS rates were 
      94.8% in patients with low MTV and TLG, and 62.1% and 63.2% in patients with high 
      MTV and TLG, respectively (P < 0.001). The 5-year OS rates were 92.6% and 92.4% 
      in patients with low MTV and TLG, and 63.3% and 64.3% in patients with high MTV 
      and TLG, respectively (P < 0.001). CONCLUSIONS: Metabolic tumor volume and TLG on 
      preoperative PET/CT were independent prognostic factors for EHMFS and OS but not 
      IHRFS in patients with very early/early HCC. Therefore, patients with high MTV or 
      TLG should be closely observed for extrahepatic metastasis using systemic 
      evaluations.
FAU - Hwang, Sang Hyun
AU  - Hwang SH
AD  - From the *Department of Nuclear Medicine, Severance Hospital, Yonsei University 
      College of Medicine, Seoul; daggerDepartment of Nuclear Medicine, International St. 
      Mary's Hospital, Catholic Kwandong University College of Medicine, Incheon; and 
      double daggerDepartment of Surgery, Severance Hospital, Yonsei University College of 
      Medicine, Seoul, South Korea.
FAU - Lee, Jeong Won
AU  - Lee JW
FAU - Cho, Ho Jin
AU  - Cho HJ
FAU - Kim, Kyung Sik
AU  - Kim KS
FAU - Choi, Gi Hong
AU  - Choi GH
FAU - Yun, Mijin
AU  - Yun M
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PL  - United States
TA  - Clin Nucl Med
JT  - Clinical nuclear medicine
JID - 7611109
RN  - 0 (Radiopharmaceuticals)
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Hepatocellular/*diagnostic imaging/metabolism
MH  - Female
MH  - *Fluorodeoxyglucose F18/metabolism
MH  - *Glycolysis
MH  - Humans
MH  - Liver Neoplasms/*diagnostic imaging/metabolism
MH  - Male
MH  - Middle Aged
MH  - *Positron Emission Tomography Computed Tomography
MH  - Predictive Value of Tests
MH  - *Radiopharmaceuticals
EDAT- 2016/10/25 06:00
MHDA- 2017/01/10 06:00
CRDT- 2016/10/25 06:00
PHST- 2016/10/25 06:00 [pubmed]
PHST- 2017/01/10 06:00 [medline]
PHST- 2016/10/25 06:00 [entrez]
AID - 10.1097/RLU.0000000000001449 [doi]
PST - ppublish
SO  - Clin Nucl Med. 2017 Jan;42(1):34-39. doi: 10.1097/RLU.0000000000001449.